MODERN GLP-1 BASED PHARMACOTHERAPY FOR SEVERE ADOLESCENT OBESITY: CLINICAL PROMISE, SAFETY CONCERNS, AND ETHICAL CHALLENGES
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5185Keywords:
Obesity, Glucagon-like Peptide-1 receptor agonists, Personalized Therapy, Childhood ObesityAbstract
Childhood obesity is an emerging worldwide health crisis, which has far-reaching harmful impacts on the health and development of affected adolescents (Hesketh et al., 2024; Li et al., 2024; Marcus et al., 2022). Innovative therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown great promise as pharmacological intervention, with substantive clinical benefit to the population. This review provides a detailed synthesis of GLP-1RAs from the perspectives of their pharmacological mechanisms, clinical potential in adolescents, safety profiles and associated ethical and social considerations. The pharmacological rationale for GLP-1RAs is due to their ability to mimic the effect of endogenous GLP-1, a hormone which plays an important role in maintaining glucose homeostasis and in regulating appetite (Moiz et al., 2025; Muzurović et al., 2022). These agents promote glucose-dependent insulin secretion, reduce glucagon release and also slow gastric emptying, thereby attenuating glycaemic excursions after a meal and promoting satiety (Alharbi, 2025; Drucker, 2021; Shah & Vella, 2014). Importantly, GLP-1RAs also activate receptors in the central nervous system to reduce hunger and food intake, which result in weight loss of significant and sustained magnitude (Dailey & Moran, 2013; Hayes, 2012; Moiz et al., 2025). This multifaceted mechanism is the basis of their efficacy to treat both type 2 diabetes and obesity. Within the adolescent age group, GLP-1RAs have shown significant clinical potential especially with liraglutide and semaglutide.Liraglutide, approved for people aged 12-17 years, has led to better body mass index (BMI) z-score and clinically significant reduction in weight compared with placebo (Berman et al., 2023; Jensterle & Janež, 2021). Semaglutide, which is approved for adolescents 12+ years, continues to push the efficacy bar and confirmatory trials have reported mean BMI reductions of over 16% with a high prevalence of participants achieving significant weight loss (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Beyond reducing weight, GLP-1RAs improve key metabolic markers - triglycerides, total cholesterol, HbA1c and systolic blood pressure - which reduces the risk of cardiovascular and type 2 diabetes in the long term (Silvia et al., 2021; Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Moreover, these medications improve weight-related quality of life, especially the physical comfort, which addresses the psychological burden of obesity in youth (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023).
Despite their efficacy, GLP-1RAs are a unique category of pharmacologic agents with regard to safety profile that requires close scrutiny. Frequently encountered adverse events are gastrointestinal in nature - nausea, vomiting, diarrhoea and constipation - generally being mild, transient and amenable to dose titration (Santos & Castro, 2025; Silvia et al., 2021). More serious issues include proven risks of cholelithiasis and acute pancreatitis, as seen in some trials (Weghuber et al., 2022; Woronow et al., 2022). A black box warning (defined by FDA) is used to alert clinicians to the potential risk of thyroid C-cells tumours, such as medullary thyroid carcinoma, based on rodent studies, and therefore require contraindication in certain clinical situations (Bezin et al., 2022; Kelly & Sipos, 2024; Pasternak et al., 2024).Long-term data on the effect of GLP-1RA on adolescent growth, pubertal development and neuropsychiatric outcomes (including suicidal ideation) are still sparse and the need for continued, rigorous surveillance (Bartkoski et al., 2025; Cooper et al., 2023).
Ethical and societal considerations are very important when incorporating GLP-1RAs into the care of adolescents. Challenges include the need for truly informed consent, and respect for adolescent autonomy, in particular because of the chronic nature of therapy (Turhal & Bağlam, 2025; Viner et al., 2020). Dramatic increases in cost and poor insurance coverage create important equity issues, which may serve to exacerbate health disparities (Berman et al., 2023; Wright et al., 2023). Societal stigma against obesity and the potential for reinforcing a "weight-normative" paradigm or misuse for cosmetic purposes also need to be watched out for (Button et al., 2025; Cominato et al., 2021; Floegel‐Shetty, 2023). A holistic approach that goes beyond simply reducing weight to include but is not limited to metabolic health, psychological wellbeing, and quality of life is crucial to ethical and effective practice. In conclusion, GLP-1RAs have been shown to be a transformational approach in the management of severe obesity in adolescents, but their introduction into the clinic will need to be accompanied by a commitment to long-term safety studies and equitable and patient-centred care.
References
Alharbi, A. (2025). GLP-1 receptor agonism: A transformative approach for managing type-2 diabetes and obesity. Saudi Pharmaceutical Journal, 33(5). https://doi.org/10.1007/s44446-025-00038-y
Ali, A. T., Al-Ani, O., & Al-Ani, F. (2024). Children’s behaviour and childhood obesity. Pediatric Endocrinology Diabetes and Metabolism, 30(3), 148. https://doi.org/10.5114/pedm.2024.142586
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R. E., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025). Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential. Toxicology Reports, 14, 101895. https://doi.org/10.1016/j.toxrep.2025.101895
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021). How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 10(7). https://doi.org/10.1530/EC-21-0130
Balachandra, S., Syed, R., Song, Z., Kasmirski, J. A., Gillis, A., Fazendin, J., Lindeman, B., & Chen, H. (2025). Evaluating thyroid cancer risk in glucagon-like peptide-1 analog users with thyroid nodules. Journal of Surgical Research, 312, 104. https://doi.org/10.1016/j.jss.2025.05.016
Bartkoski, M., Poweleit, E. A., & Stancil, S. L. (2025). GLP-1 agonists for pediatric psychopharmacology: Opportunities and cautions. Clinical and Translational Science, 18(6). https://doi.org/10.1111/cts.70262
Bensignor, M. O., Arslanian, S., & Vajravelu, M. E. (2024). Semaglutide for management of obesity in adolescents: Efficacy, safety, and considerations for clinical practice. Current Opinion in Pediatrics, 36(4), 449. https://doi.org/10.1097/MOP.0000000000001365
Berman, C., Vidmar, A. P., & Chao, L. C. (2023). Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes in youth. touchREVIEWS in Endocrinology, 19(1), 38. https://doi.org/10.17925/EE.2023.19.1.38
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J. (2022). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 46(2), 384. https://doi.org/10.2337/dc22-1148
Blaauwendraad, S. M., Kamphuis, A. S., Ruiz-Ojeda, F. J., Brandimonte-Hernández, M., Ventura, E. F., Abrahamse-Berkeveld, M., Collado, M. C., van Diepen, J. A., Iozzo, P., Knipping, K., Bouwman, C. A., Gil, Á., & Gaillard, R. (2024). Risk factors in the first 1000 days of life associated with childhood obesity: A systematic review and risk factor quality assessment. medRxiv. https://doi.org/10.1101/2024.06.26.24309514
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024). Glucagon-like peptide-1: New regulator in lipid metabolism. Diabetes & Metabolism Journal, 48(3), 354. https://doi.org/10.4093/dmj.2023.0277
Button, A. M., Persaud, A., Tanner, A. B., Balantekin, K. N., Tanofsky-Kraff, M., Jebeile, H., & Wilfley, D. E. (2025). Intersection between eating disorders and obesity in youth: Implications for treatment. Current Obesity Reports, 14(1). https://doi.org/10.1007/s13679-025-00664-6
Calcaterra, V., & Zuccotti, G. (2022). Prevention and treatment of cardiometabolic diseases in children with overweight and obesity: The future of healthcare. Children, 9(2), 176. https://doi.org/10.3390/children9020176
Cominato, L., Franco, R. R., & Damiani, D. (2021). Adolescent obesity treatments: News, views, and evidence. Archives of Endocrinology and Metabolism. https://doi.org/10.20945/2359-3997000000393
Cominato, L., de Resende, M. L., Bernardes, N. M. C., Rachid, L. L., Passone, C., Mattar, L. B. F., Neme, G., de Souza, S. F. L., dos Santos, C. R. P., Franco, R. R., & Damiani, D. (2025). 12-month outcomes of GLP-1 in severe pediatric obesity: Real-world data. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1663499
Cooper, D. M., Rothstein, M. A., Amin, A., Hirsch, J. D., & Cooper, E. (2023). Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action. Journal of Clinical and Translational Science, 7(1). https://doi.org/10.1017/cts.2023.612
Dailey, M. J., & Moran, T. H. (2013). Glucagon-like peptide 1 and appetite. Trends in Endocrinology and Metabolism, 24(2), 85. https://doi.org/10.1016/j.tem.2012.11.008
Denova-Gutiérrez, E., Méndez-Sánchez, L., Araiza-Nava, B., González-Rocha, A., Shamah, T., Bonvechio, A., Barquera, S., & Rivera, J. C. A. (2022). Overview of systematic reviews of health interventions that aim to prevent and treat overweight and obesity among children. Systematic Reviews, 11(1). https://doi.org/10.1186/s13643-022-02047-7
Drucker, D. J. (2021). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. https://doi.org/10.1016/j.molmet.2021.101351
Floegel-Shetty, A. (2023). Should pharmaceuticals be used as weight loss interventions for adolescents classified as obese by BMI? AMA Journal of Ethics, 25(7). https://doi.org/10.1001/amajethics.2023.478
Först, T., Block, C. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025). Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16247
Gao, L., Peng, W., Xue, H., Wu, Y., Zhou, H., Jia, P., & Wang, Y. (2023). Spatial–temporal trends in global childhood overweight and obesity from 1975 to 2030: A weight mean center and projection analysis of 191 countries. Globalization and Health, 19(1). https://doi.org/10.1186/s12992-023-00954-5
Hayes, M. R. (2012). Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiology & Behavior, 106(3), 413. https://doi.org/10.1016/j.physbeh.2012.02.017
Hesketh, K. D., Zheng, M., & Campbell, K. J. (2024). Early life factors that affect obesity and the need for complex solutions. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-024-01035-2
Holst, J. J. (2024). GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nature Metabolism, 6(10), 1866. https://doi.org/10.1038/s42255-024-01113-9
Hüls, A., Wright, M. N., Bogl, L. H., Kaprio, J., Lissner, L., Molnár, D., Moreno, L. A., De Henauw, S., Siani, A., Veidebaum, T., Ahrens, W., Pigeot, I., & Foraita, R. (2021). Polygenic risk for obesity and its interaction with lifestyle and sociodemographic factors in European children and adolescents. International Journal of Obesity, 45(6), 1321. https://doi.org/10.1038/s41366-021-00795-5
Jacobsen, L. V., Flint, A., Olsen, A., & Ingwersen, S. H. (2015). Liraglutide in type 2 diabetes mellitus: Clinical pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 55(6), 657. https://doi.org/10.1007/s40262-015-0343-6
Jensterle, M., & Janež, A. (2021). Glucagon-like peptide-1 receptor agonists in the treatment of obesity. Hormone Research in Paediatrics, 96(6), 599. https://doi.org/10.1159/000521264
Jiang, Y., Hu, J., Chen, F., Liu, B., Wei, M., Xia, W., Yan, Y., Xie, J., Du, S., Tian, X., Aris, I. M., Wang, Y., & Zhang, J. (2025). Comprehensive systematic review and meta-analysis of risk factors for childhood obesity in China and future intervention strategies. The Lancet Regional Health – Western Pacific, 58, 101553. https://doi.org/10.1016/j.lanwpc.2025.101553
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021). Contemporary classification of glucagon-like peptide 1 receptor agonists (GLP1RAs). Diabetes Therapy, 12(8), 2133. https://doi.org/10.1007/s13300-021-01113-y
Kelly, C. A., & Sipos, J. A. (2024). Approach to the patient with thyroid nodules: Considering GLP-1 receptor agonists. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae722
Kerr, J. A., Patton, G., Cini, K., Abate, Y. H., Abbas, N., Magied, A. H. A. A. A., ElHafeez, S. A., Abd-Elsalam, S., Abdollahi, A., Abdoun, M., Abdulah, D. M., Abdulkader, R. S., Abdullahi, A., Abeywickrama, H. M., Abie, A., Abiodun, O., Abohashem, S., Abtahi, D., Abualruz, H., … Alvis-Guzmán, N. (2025). Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: A forecasting study for the Global Burden of Disease Study 2021. The Lancet, 405(10481), 785. https://doi.org/10.1016/S0140-6736(25)00397-6
Kornelius, E., Huang, J., Lo, S., Huang, C., & Yang, Y. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports, 14(1), 24433. https://doi.org/10.1038/s41598-024-75965-2
Li, H., Xiang, X., Yi, Y., Yan, B., Yi, L., Ding, N., Yang, J., Gu, Z., Luo, Q., Huang, Y., Fan, L., & Wei, X. (2024). Epidemiology of obesity and influential factors in China: A multicenter cross-sectional study of children and adolescents. BMC Pediatrics, 24(1), 498. https://doi.org/10.1186/s12887-024-04970-1
Ling, J., Chen, S., Zahry, N. R., & Kao, T. A. (2022). Economic burden of childhood overweight and obesity: A systematic review and meta-analysis. Obesity Reviews, 24(2). https://doi.org/10.1111/obr.13535
Maccarini, B., Loperfido, F., Bianco, I., Sottotetti, F., Masri, D. E., Ferrara, C., Verme, F., Cangelosi, E., Meriggi, N., Filippo, C. D., Cena, H., & Giuseppe, R. D. (2025). Offspring’s exposome: A narrative review on the influence of early-life factors on childhood obesity risk. Frontiers in Nutrition, 12, 1597746. https://doi.org/10.3389/fnut.2025.1597746
Marcus, C., Danielsson, P., & Hagman, E. (2022). Pediatric obesity—Long-term consequences and effect of weight loss. Journal of Internal Medicine, 292(6), 870. https://doi.org/10.1111/joim.13547
Mazza, O., Gluck, C., Haim, A., & Bornstein, R. J. (2025). Spatial patterns of childhood obesity clusters linked to socioeconomic inequalities. Frontiers in Public Health, 13. https://doi.org/10.3389/fpubh.2025.1497090
Miñambres, I., & Pérez, A. (2017). Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? Diabetology & Metabolic Syndrome, 9(1). https://doi.org/10.1186/s13098-017-0204-6
Mohamed, M. A. S., AbouKhatwa, M. M., Saifullah, A. A., Syahmi, M. H., Mosaad, M., Elrggal, M. E., Dehele, I. S., & Elnaem, M. H. (2022). Risk factors, clinical consequences, prevention, and treatment of childhood obesity. Children, 9(12), 1975. https://doi.org/10.3390/children9121975
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine, 138(6), 934. https://doi.org/10.1016/j.amjmed.2025.01.021
Muzurović, E., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022). Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease—Current evidence. Journal of Cardiovascular Pharmacology and Therapeutics, 27. https://doi.org/10.1177/10742484221146371
O’Connor, E., Evans, C. V., Henninger, M. L., Redmond, N., & Senger, C. A. (2024). Interventions for weight management in children and adolescents. JAMA, 332(3), 233. https://doi.org/10.1001/jama.2024.6739
Pabreja, K., Wahid, M. E. A., Koole, C., Wootten, D., & Furness, S. G. B. (2013). Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. British Journal of Pharmacology, 171(5), 1114. https://doi.org/10.1111/bph.12313
Pacocha, N., Jędrychowski, J., Karpowicz, N., Krzyżanowska, M., Zgierska, M., Kaszucka, J., Raczyńska, A., Kosiec, K., Krzemień, O., & Kwiecień, I. (2024). Long-term consequences of childhood and adolescent obesity on physical and mental health: Implications for adult life. Importance of prevention. International Journal of Innovative Technologies in Social Science. https://doi.org/10.31435/ijitss.4(44).2024.3051
Panera, N., Mandato, C., Crudele, A., Bertrando, S., Vajro, P., & Alisi, A. (2022). Genetics, epigenetics and transgenerational transmission of obesity in children. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.1006008
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Guðbjörnsdóttir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ, 385. https://doi.org/10.1136/bmj-2023-078225
Saliba, K., & Cuschieri, S. (2021). Amidst the COVID-19 pandemic childhood obesity is still an epidemic—Spotlight on obesity’s multifactorial determinants. Health Sciences Review, 1, 100006. https://doi.org/10.1016/j.hsr.2021.100006
Santos, B., & Castro, R. S. (2025). Efeitos adversos dos análogos do GLP-1: Uma revisão sistemática. Research, Society and Development, 14(1). https://doi.org/10.33448/rsd-v14i1.47981
Segal, A. B., Huerta, M. del C., Aurino, E., & Sassi, F. (2020). The impact of childhood obesity on human capital in high-income countries: A systematic review. Obesity Reviews, 22(1). https://doi.org/10.1111/obr.13104
Sfairopoulos, D., Liatis, S., Tigas, S., & Liberopoulos, E. (2018). Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones, 17(3), 333. https://doi.org/10.1007/s42000-018-0038-0
Shah, M., & Vella, A. (2014). Effects of GLP-1 on appetite and weight. Reviews in Endocrine and Metabolic Disorders, 15(3), 181. https://doi.org/10.1007/s11154-014-9289-5
Silvia, C., F., M., Simona, Umberto, C., Patrizia, B., Laura, L., Barbara, P., & Lorenzo, I. (2021). Abstracts. Hormone Research in Paediatrics, 94, 1. https://doi.org/10.1159/000518849
Šket, R., Slapnik, B., Kotnik, P., Črepinšek, K., Kern, B. Č., Tesovnik, T., Bizjan, B. J., Vrhovšek, B., Remec, Ž. I., Debeljak, M., Battelino, T., & Kovač, J. (2024). Integrating genetic insights, technological advancements, screening, and personalized pharmacological interventions in childhood obesity. Advances in Therapy. https://doi.org/10.1007/s12325-024-03057-8
Stefater-Richards, M. A., Jhe, G., & Zhang, Y. J. (2025). GLP-1 receptor agonists in pediatric and adolescent obesity. Pediatrics. https://doi.org/10.1542/peds.2024-068119
Suter, B., Rhodes, A., Bigeh, A., Frommeyer, T. C., & Mehta, L. S. (2025). The role of GLP-1RA medications in medical weight loss and the positive impacts on lipid management. Current Cardiovascular Risk Reports, 19(1). https://doi.org/10.1007/s12170-025-00761-0
Tahrani, A. A., Barnett, A., & Bailey, C. J. (2016). Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology, 12(10), 566. https://doi.org/10.1038/nrendo.2016.86
Tamayo-Trujillo, R., Ruiz-Pozo, V. A., Cadena-Ullauri, S., Guevara-Ramírez, P., Paz-Cruz, E., Zambrano-Villacres, R., Simancas-Racines, D., & Zambrano, A. K. (2024). Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Frontiers in Nutrition, 11. https://doi.org/10.3389/fnut.2024.1398059
Tully, L., Arthurs, N., Wyse, C., Browne, S., Case, L., McCrea, L., O’Connell, J., O’Gorman, C., Smith, S. M., Walsh, A., Ward, F., & O’Malley, G. (2022). Guidelines for treating child and adolescent obesity: A systematic review. Frontiers in Nutrition, 9. https://doi.org/10.3389/fnut.2022.902865
Turhal, T., & Bağlam, N. (2025). Bariatric surgery in adolescent obesity: A review of current evidence. DergiPark (Istanbul University). https://doi.org/10.51972/tfsd.1749670
Vajravelu, M. E., Tas, E., & Arslanian, S. (2023). Pediatric obesity: Complications and current day management. Life, 13(7), 1591. https://doi.org/10.3390/life13071591
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024). The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: A systematic review. Current Treatment Options in Psychiatry. https://doi.org/10.1007/s40501-024-00331-y
Viner, R., Kinra, S., Christie, D., Cole, T., Costa, S., Croker, H., Fry, T., Hsia, Y., Hudson, L., Kessel, A., Morris, S., Nazareth, I., Nicholls, D., Park, M. H., Saxena, S., Taylor, B., White, B., & Wong, I. C. K. (2020). Improving the assessment and management of obesity in UK children and adolescents: The PROMISE research programme including a RCT. Programme Grants for Applied Research, 8(3), 1. https://doi.org/10.3310/pgfar08030
Vourdoumpa, A., Paltoglou, G., & Charmandari, E. (2023). The genetic basis of childhood obesity: A systematic review. Nutrients, 15(6), 1416. https://doi.org/10.3390/nu15061416
Wang, Y. (2021). Potential mechanisms in childhood obesity: Causes and prevention. Europe PMC. https://europepmc.org/article/MED/33534460
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022). Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine, 387(24), 2245. https://doi.org/10.1056/NEJMoa2208601
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., OK, J., AS, K., LD, M., Sørrig, R., Arslanian, S., & STEP, T. I. (2023). Once-weekly semaglutide in adolescents with obesity. Yearbook of Pediatric Endocrinology. https://doi.org/10.1530/ey.20.9.17
Weghuber, D., Kelly, A. S., & Arslanian, S. (2023). Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine, 388(12), 1145. https://doi.org/10.1056/NEJMc2300510
Wilbon, S. S., & Kolonin, M. G. (2023). GLP1 receptor agonists—Effects beyond obesity and diabetes. Cells, 13(1), 65. https://doi.org/10.3390/cells13010065
Wójcik, M., Álvarez-Pitti, J., Kozioł-Kozakowska, A., Brzeziński, M., Gabbianelli, R., Herceg-Čavrak, V., Wühl, E., Lucas, I., Radovanović, D., Melk, A., López-Valcárcel, B. G., Fernández-Aranda, F., Mazur, A., Lurbe, E., Borghi, C., & Drożdż, D. (2023). Psychosocial and environmental risk factors of obesity and hypertension in children and adolescents—A literature overview. Frontiers in Cardiovascular Medicine, 10, 1268364. https://doi.org/10.3389/fcvm.2023.1268364
Woronow, D., Chamberlain, C., Niak, A., Avigan, M., Houstoun, M., & Kortepeter, C. (2022). Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration. JAMA Internal Medicine, 182(10), 1104. https://doi.org/10.1001/jamainternmed.2022.3810
Wright, D. R., Luviano, A., & Skelton, J. A. (2023). Interpreting cost-effectiveness analyses of anti-obesity medications for the treatment of adolescent obesity—Reading the tea leaves. JAMA Network Open, 6(8). https://doi.org/10.1001/jamanetworkopen.2023.29422
Zembura, M., Lula, P., & Matusik, P. (2023). Ten-year differences in nutritional status and obesity-related risk factors in Polish preschool children. Children, 10(4), 636. https://doi.org/10.3390/children10040636
Zhang, X., Liu, J., Ni, Y., Yi, C., Fang, Y., Ning, Q., Shen, B., Zhang, K., Liu, Y., Yang, L., Li, K., Liu, Y., Huang, R., & Li, Z. (2024). Global prevalence of overweight and obesity in children and adolescents. JAMA Pediatrics, 178(8), 800. https://doi.org/10.1001/jamapediatrics.2024.1576
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021). GLP-1 receptor agonists: Beyond their pancreatic effects. Frontiers in Endocrinology, 12. https://doi.org/10.3389/fendo.2021.721135
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Agata Porwolik, Hanna Porwolik, Patryk Cyran, Radosław Szydłowski, Magdalena Bodera, Marek Skotarski
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
